Parabilis IPO Expansion

Summary Parabilis, formerly FogPharma, increased its planned IPO size to as much as $636.8 million, potentially becoming one of the largest biotech IPOs in recent years. The financing represents a major validation event for the company’s Helicon peptide platform and antibody-helicon conjugate strategy targeting historically…